Bioworkshops’ Biosimilar Platform focuses on high-value, high-demand targets across a broad range of therapeutic areas, with over 66 biosimilar molecules developed, and leverages a robust process development platform to achieve biosimilarity, CQA consistency, and scalable GMP supply—supporting global development and registration. 10+ Biosimilar NDA Experience.
Built on fully licensed ATCC CHO-K1 cells and supported by US DMF registration, our royalty-free CHO platform provides a compliant, scalable foundation for biosimilar development. Through optimized vector engineering and clone selection, we consistently achieve:
Titers >5 g/LStable long-term productivity
Proven scalability of key quality attributes
Product quality remains consistent from development to scale-up, enabling high similarity to reference products across mAbs and bispecific formats.
Bioworkshops deliver a high degree of biosimilarity by integrating cell line engineering, process optimization, and advanced analytical comparability studies. Through rigorous control of critical quality attributes (CQAs), we ensure structural and functional comparability to the reference product within predefined regulatory acceptance criteria across development and scale-up.
Our biosimilar platform is built on strong technical robustness and regulatory confidence, providing a reliable foundation for efficient and competitive development.
High Similarity Assurance
Proven Scalability
Robust Process Control
Freedom to Operate
Reference Product
Biosimilar Product
The following examples represent part of our portfolio. Contact us to explore additional biosimilar assets available for development or licensing.
A biosimilar is a biological product that is highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or potency.
Unlike generic drugs, biosimilars are developed through comprehensive analytical, functional, and clinical comparability studies due to the complexity of biologics.
Biologics are produced in living systems, and slight variations in:
may occur.
Regulatory authorities require demonstration of high similarity within an acceptable scientific range.
Our biosimilar development services cover the full CMC pathway, including:
We provide an integrated strategy from gene sequence to commercial manufacturing readiness.
We support biosimilar programs across the full development lifecycle, including:
Our engagement models are flexible and adaptable to client needs. We offer stage-based collaboration, integrated end-to-end development, co-development partnerships, and customized project structures to accommodate different pipeline strategies and risk-sharing preferences.
